Skip to main content
Atrás
SHEZF logo

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Calidad de datos: 100%
Sobrecompra
SHEZF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.47
$0.00 (0.00%)
Cap. Mercado: 690.29M
Rango del Día
$0.47 $0.72
Rango de 52 Semanas
$0.47 $0.72
Volumen
25
Promedio 50D / 200D
$0.47 / $0.47
Cierre Anterior
$0.47

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 1.1 0.4
P/B 0.1 2.9
ROE % 5.4 3.8
Net Margin % 12.3 3.9
Rev Growth 5Y % -0.2 10.0
D/E 0.3 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 $0.53
$0.53 – $0.53
 6.2 B 1
FY2026 $0.49
$0.49 – $0.49
 5.8 B 1

Puntos Clave

Revenue declined -0.24% annually over 5 years
Debt/Equity of 0.25 — conservative balance sheet
Generating 1.99B in free cash flow
P/E of 1.07 — trading at a low valuation
Cash machine — converts 307.91% of earnings into free cash flow
Capital efficient — spends only 3.84% of revenue on capex

Crecimiento

Revenue Growth (5Y)
-0.24%
Revenue (1Y)-3.03%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
5.38%
ROIC3.68%
Net Margin12.25%
Op. Margin14.04%

Seguridad

Debt / Equity
0.25
Current Ratio2.60
Interest Coverage5.25

Valoración

P/E Ratio
1.07
P/B Ratio0.06
EV/EBITDA2.67
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3.03% Revenue Growth (3Y) -14.12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -5.71%
Revenue Growth (5Y) -0.24% Earnings Growth (5Y) -10.86%
Profitability
Revenue (TTM) 5.28B Net Income (TTM) 646.74M
ROE 5.38% ROA 3.73%
Gross Margin 33.26% Operating Margin 14.04%
Net Margin 12.25% Free Cash Flow (TTM) 1.99B
ROIC 3.68% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.25 Current Ratio 2.60
Interest Coverage 5.25 Dividend Yield 0.03%
Valuation
P/E Ratio 1.07 P/B Ratio 0.06
P/S Ratio 0.13 PEG Ratio -0.04
EV/EBITDA 2.67 Dividend Yield 0.03%
Market Cap 690.29M Enterprise Value 1.98B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 5.28B 5.45B 7.16B 6.37B 5.33B
Net Income 646.74M -783.26M 727.43M 240.79M 1.02B
EPS (Diluted) 0.44 -0.53 0.50 0.16 0.76
Gross Profit 1.76B 944.92M 2.33B 2.03B 2.09B
Operating Income 741.31M -860.91M 828.62M 227.47M 1.33B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 17.34B 19.20B 20.81B 19.11B 19.03B
Total Liabilities 5.14B 7.22B 8.41B 7.58B 7.34B
Shareholders' Equity 12.15B 11.91B 12.31B 11.41B 11.57B
Total Debt 2.98B 3.78B 6.46B 5.65B 5.65B
Cash & Equivalents 1.69B 1.85B 2.14B 2.94B 2.71B
Current Assets 9.62B 10.60B 12.39B 10.77B 9.13B
Current Liabilities 3.70B 4.99B 5.58B 4.79B 3.61B

Puntuaciones de Estrategias

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#284 of 820
51
Value Defensive Investing (Benjamin Graham)
#174 of 708
45

Actividad Reciente

Entró Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entró Defensive Investing (Benjamin Graham)
Mar 24, 2026